DK3280440T3 - Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3280440T3
DK3280440T3 DK16777134.4T DK16777134T DK3280440T3 DK 3280440 T3 DK3280440 T3 DK 3280440T3 DK 16777134 T DK16777134 T DK 16777134T DK 3280440 T3 DK3280440 T3 DK 3280440T3
Authority
DK
Denmark
Prior art keywords
antibodies
methods
humanized anti
humanized
Prior art date
Application number
DK16777134.4T
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Application granted granted Critical
Publication of DK3280440T3 publication Critical patent/DK3280440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK16777134.4T 2015-04-06 2016-04-05 Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf DK3280440T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143636P 2015-04-06 2015-04-06
US201562200997P 2015-08-04 2015-08-04
PCT/US2016/026038 WO2016164358A1 (en) 2015-04-06 2016-04-05 Humanized anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3280440T3 true DK3280440T3 (da) 2023-02-20

Family

ID=57073330

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16777134.4T DK3280440T3 (da) 2015-04-06 2016-04-05 Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf

Country Status (27)

Country Link
US (3) US10729767B2 (da)
EP (2) EP3280440B1 (da)
JP (3) JP7005483B2 (da)
KR (1) KR20180006379A (da)
CN (2) CN117285634A (da)
AU (2) AU2016246452B2 (da)
BR (1) BR112017021289A2 (da)
CA (1) CA2981321A1 (da)
CL (1) CL2017002514A1 (da)
CO (1) CO2017011238A2 (da)
DK (1) DK3280440T3 (da)
EA (1) EA201792080A1 (da)
ES (1) ES2938359T3 (da)
FI (1) FI3280440T3 (da)
HK (2) HK1250930A1 (da)
HR (1) HRP20230093T1 (da)
HU (1) HUE061076T2 (da)
IL (2) IL254670B2 (da)
LT (1) LT3280440T (da)
MX (2) MX2017012834A (da)
PH (1) PH12017501815A1 (da)
PL (1) PL3280440T3 (da)
PT (1) PT3280440T (da)
RS (1) RS63956B1 (da)
SG (2) SG11201707886WA (da)
SI (1) SI3280440T1 (da)
WO (1) WO2016164358A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
MX2015014017A (es) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Variante de la region fc.
IL254670B2 (en) 2015-04-06 2023-04-01 Bioverativ Usa Inc Human anti-c1s antibodies and methods of using them
AU2017341766A1 (en) * 2016-10-12 2019-05-23 Bioverativ Usa Inc. Anti-C1s antibodies and methods of use thereof
EP3774892A4 (en) * 2018-04-13 2022-02-16 Chugai Seiyaku Kabushiki Kaisha ANTIBODIES TO A COMPONENT OF THE COMPLEMENT AND METHODS OF USE
WO2022031978A1 (en) 2020-08-06 2022-02-10 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
US20240117021A1 (en) 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
JP4077030B2 (ja) 1993-09-01 2008-04-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 急性心筋梗塞中の心筋傷害の低減方法
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2003529536A (ja) 1999-02-09 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物
AU4369000A (en) 1999-04-26 2000-11-10 Duke University Inhibition of complement action
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
WO2001098365A2 (en) 2000-06-21 2001-12-27 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement c1s
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
US20080206242A1 (en) * 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
JP4601426B2 (ja) 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TR201708554T4 (tr) 2004-06-10 2019-02-21 Omeros Corp Masp-2 ye bağlı tamamlayıcı aktivasyon ile ilişkili durumların tedavisi için yöntemler.
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
CA2601523A1 (en) 2005-03-16 2006-09-28 Janssen Pharmaceutica N.V. Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
AU2007223796B2 (en) 2006-03-08 2013-01-24 Iveric Bio., Inc. Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
ES2616204T3 (es) 2006-09-05 2017-06-09 Alexion Pharmaceuticals, Inc. Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
ES2831325T3 (es) 2006-10-10 2021-06-08 Regenesance B V Inhibición del complemento para una mejor regeneración de los nervios
TW200844079A (en) 2006-12-19 2008-11-16 Versitech Ltd Synthetic ion channels
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
EP3101031A1 (en) 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP5792626B2 (ja) 2008-12-01 2015-10-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 補体固定抗体の検出のための方法および組成物
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US8883985B2 (en) * 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
SG183541A1 (en) 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
CN105963694B (zh) 2010-04-30 2019-11-05 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
AU2011256290B2 (en) 2010-05-17 2014-06-12 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2013533243A (ja) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
PL2648752T3 (pl) 2010-12-06 2017-07-31 Seattle Genetics, Inc. Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka
KR101720562B1 (ko) 2011-04-08 2017-03-30 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
CA3025762C (en) 2011-05-04 2021-11-09 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
ES2587863T3 (es) 2011-12-22 2016-10-27 Csl Behring Gmbh Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central
JP6081699B2 (ja) * 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
AU2014213147B2 (en) 2013-01-31 2019-01-17 lmmunAbs Inc. C5 antibody and method for preventing and treating complement-related diseases
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
IL254670B2 (en) 2015-04-06 2023-04-01 Bioverativ Usa Inc Human anti-c1s antibodies and methods of using them
BR112017027578A2 (pt) 2015-06-26 2018-08-28 Bioverativ Usa Inc métodos de tratamento de distúrbios autoimunes e aloimunes
AU2017341766A1 (en) 2016-10-12 2019-05-23 Bioverativ Usa Inc. Anti-C1s antibodies and methods of use thereof
TW201842931A (zh) 2017-03-14 2018-12-16 美商生物維瑞提夫美國公司 用於治療補體介導之疾病及病症之方法

Also Published As

Publication number Publication date
US10729767B2 (en) 2020-08-04
AU2022203679A1 (en) 2022-06-16
US20200405852A1 (en) 2020-12-31
US20230218753A1 (en) 2023-07-13
BR112017021289A2 (pt) 2018-06-26
IL298180A (en) 2023-01-01
IL254670B (en) 2022-12-01
WO2016164358A1 (en) 2016-10-13
CN108348598B (zh) 2023-09-01
EP3280440A4 (en) 2018-08-29
PT3280440T (pt) 2023-02-14
EP3280440A1 (en) 2018-02-14
JP7005483B2 (ja) 2022-02-10
MX2017012834A (es) 2018-05-28
AU2016246452A1 (en) 2017-10-19
FI3280440T3 (fi) 2023-03-09
CN117285634A (zh) 2023-12-26
HUE061076T2 (hu) 2023-05-28
CA2981321A1 (en) 2016-10-13
JP2021006544A (ja) 2021-01-21
JP7153696B2 (ja) 2022-10-14
HK1250930A1 (zh) 2019-01-18
EP4212175A1 (en) 2023-07-19
SG10201909180SA (en) 2019-11-28
ES2938359T3 (es) 2023-04-10
CL2017002514A1 (es) 2018-04-20
EP3280440B1 (en) 2022-11-16
PH12017501815A1 (en) 2018-04-23
JP2022078221A (ja) 2022-05-24
HK1259251A1 (zh) 2019-11-29
US20180092974A1 (en) 2018-04-05
AU2016246452B2 (en) 2022-03-10
KR20180006379A (ko) 2018-01-17
HRP20230093T1 (hr) 2023-03-31
EA201792080A1 (ru) 2018-03-30
RS63956B1 (sr) 2023-02-28
IL254670B2 (en) 2023-04-01
US11246926B2 (en) 2022-02-15
SI3280440T1 (sl) 2023-03-31
CO2017011238A2 (es) 2018-01-16
LT3280440T (lt) 2023-02-27
PL3280440T3 (pl) 2023-06-19
JP2018513213A (ja) 2018-05-24
CN108348598A (zh) 2018-07-31
SG11201707886WA (en) 2017-10-30
MX2022001085A (es) 2022-02-14
IL254670A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3551660T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3515478T3 (da) Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3292149T3 (da) Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf
HK1253235A1 (zh) 抗tigit抗原結合蛋白及其使用方法
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3280440T3 (da) Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
DK3390442T3 (da) Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
DK3157959T3 (da) Monoklonale antistoffer mod her2-epitop og fremgangsmåder til anvendelse deraf